Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Newer antihypertensive drugs

J R Gregoire1, S G Sheps

  • 1Division of Hypertension and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Current Opinion in Cardiology
|September 1, 1995
PubMed
Summary

Discover new antihypertensive drugs: imidazolines offer fewer side effects than older central agents. Monatepil shows potential for lowering blood pressure, cholesterol, and preventing atherosclerosis. Neutral endopeptidase inhibitors present another novel approach.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical decision-making in hypertension using an automated (BpTRU) measurement device.

Journal of human hypertension·2004
Same author

Martorell's hypertensive leg ulcer: case report and concise review of the literature.

Journal of human hypertension·2001
Same author

Reflections on the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Current hypertension reports·2000
Same author

[Comments on the 6th Report of the Joint American Committee on the Diagnosis and Treatment of Arterial Hypertension].

Revista espanola de cardiologia·1999
Same author

Detection and control of high blood pressure in the community : Do we need a wake-up call?

Hypertension (Dallas, Tex. : 1979)·1999
Same author

Overview of JNC VI: new directions in the management of hypertension and cardiovascular risk.

American journal of hypertension·1999

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Discovery

Background:

  • Hypertension remains a significant global health challenge.
  • Development of novel antihypertensive agents with improved efficacy and side-effect profiles is crucial.
  • Existing treatments have limitations, necessitating exploration of new drug classes.

Purpose of the Study:

  • To review three emerging classes of antihypertensive medications: imidazolines, monatepil, and neutral endopeptidase inhibitors.
  • To highlight the mechanisms of action and potential benefits of these novel drug classes.
  • To assess their potential impact on cardiovascular disease management.

Main Methods:

  • Review of current literature on imidazoline receptor agonists, monatepil, and neutral endopeptidase inhibitors.
  • Analysis of pharmacological properties, clinical trial data (where available), and proposed mechanisms of action.
  • Comparative assessment of these agents against existing antihypertensive therapies.

Main Results:

  • Imidazolines represent a new generation of centrally acting antihypertensives with improved tolerability due to selective imidazoline receptor binding.
  • Monatepil exhibits dual action as a calcium and alpha-1 antagonist, lowering blood pressure and serum cholesterol, with potential antiatherosclerosis effects.
  • Neutral endopeptidase inhibitors reduce blood pressure by modulating natriuretic peptides and other vasoactive peptides.

Conclusions:

  • Imidazolines offer a promising alternative for central antihypertensive therapy with reduced side effects.
  • Monatepil presents a multi-targeted approach for hypertension and dyslipidemia, potentially impacting atherosclerosis.
  • Neutral endopeptidase inhibitors represent a novel pathway for blood pressure regulation through peptide modulation.

Related Experiment Videos